(Australia-NewsWire.Com, January 05, 2018 ) Asia Pacific Hormone Therapy (HT) remains the most effective option to treat menopausal symptoms. There are many good clinical data to indicate that the use of HT started in early menopause is effective and safe. The Asia-Pacific Hormone Replacement Therapy Market is estimated at USD 2.21 billion in 2016 and is predicted to reach USD 3.23 billion by 2021, growing at a CAGR of 7.92%.
Growing awareness on post-menopausal hazards, reimbursement policies, novel formulations, rise in unmet medical needs which require the employment of hormone therapy, benefits like lower risk of fractures are the few factors propelling the growth of Asia-Pacific hormone replacement therapy market.
The major factor acting as a hurdle for market growth in the Asia-Pacific region is the cost of therapy. Normally, the therapy costs around $ 10,000. This is a pretty high amount considering the economic conditions of people in most of the countries in the Asia-Pacific region. Further, the risk of side effects, such as bloating, mood changes, and nausea, bleeding, breast tenderness or enlargement, headaches, risk of breast cancer, heart disease, and stroke is restraining the growth of the Asia-Pacific market. Along with this, women with high susceptibility to coronary diseases are kept away from taking hormone replacement therapy.
The Asia Pacific hormone replacement therapy market is segmented on the basis of hormone type into Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid replacement therapy and others. The estrogen replacement therapy segment dominates the market, representing more than half of the market. While other therapies are still new in these regions and takes some time to get acquainted. Additionally, on the basis of route of administration the market is classified as oral, parenteral, transdermal and other routes. The oral route is regarded as one of the safest and most preferred routes of drug administration.
Market Segmentation By Hormone Type • Estrogen Replacement Therapy • Growth Hormone Replacement Therapy • Thyroid Replacement Therapy • Others By Route of Administration • Oral • Parenteral • Transdermal
Further, on the basis of geography, the Asia-Pacific hormone replacement therapy market is analysed under regions namely, India, China, Australia, Japan and South Korea. Japan holds the major share of the Asia-Pacific hormone replacement therapy market while India & China are expected to register high growth rates during the forecast period.
Some of the key players operating in the Asia-Pacific hormone replacement market are F. Hoffmann-La Roche, Novartis, Pfizer, Abbott Laboratories, Mylan Laboratories, Novo Nordisk, Amgen, Merck & Co., Bayer, Eli Lily, Wyeth and Hisamitsu Pharmaceutical Co. Inc.
About Market Data Forecast: Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact: Abhishek Shukla Sales Manager (International Business Development) Market Data Forecast Direct Line: +1-888-702-9626 Mobile: +91 998 555 0206 Mail: email@example.com